Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) announced its earnings results on Tuesday. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.01, Zacks reports.
Nautilus Biotechnology Trading Down 1.1 %
NASDAQ:NAUT traded down $0.01 during mid-day trading on Friday, hitting $0.68. The company's stock had a trading volume of 176,676 shares, compared to its average volume of 110,194. The stock has a fifty day moving average of $0.91 and a 200-day moving average of $1.67. The company has a market capitalization of $85.45 million, a price-to-earnings ratio of -1.21 and a beta of 1.39. Nautilus Biotechnology has a fifty-two week low of $0.66 and a fifty-two week high of $3.09.
Analysts Set New Price Targets
Separately, Guggenheim set a $2.50 target price on shares of Nautilus Biotechnology in a research note on Friday, February 28th.
Read Our Latest Stock Report on NAUT
Insider Buying and Selling
In related news, CEO Sujal M. Patel acquired 53,300 shares of the business's stock in a transaction on Wednesday, March 19th. The stock was bought at an average cost of $0.99 per share, with a total value of $52,767.00. Following the completion of the acquisition, the chief executive officer now owns 10,117,788 shares in the company, valued at $10,016,610.12. The trade was a 0.53 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 40.50% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Nautilus Biotechnology
An institutional investor recently raised its position in Nautilus Biotechnology stock. Bank of America Corp DE lifted its holdings in Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Free Report) by 37.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 49,419 shares of the company's stock after acquiring an additional 13,363 shares during the quarter. Bank of America Corp DE's holdings in Nautilus Biotechnology were worth $83,000 at the end of the most recent reporting period. 50.71% of the stock is owned by hedge funds and other institutional investors.
About Nautilus Biotechnology
(
Get Free Report)
Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.
See Also
Before you consider Nautilus Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nautilus Biotechnology wasn't on the list.
While Nautilus Biotechnology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
